Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Advanced Pancreatic Cancer

Advanced Pancreatic Cancer Carcinoma of the pancreas remains a lethal disease, but much progress has been made in understanding the biology of this cancer. The many genes known to be mutated in the malignant pancreatic cancer cell, especially K-ras and pl6INK4, allow the tumor to grow rapidly, metastasize early and not respond to most conventional chemotherapy agents. Combinations of newer agents that can inhibit the up-regulated growth pathway, including anti-growth factor receptor antibodies, anti-growth factor tyrosine kinases, anti-ras molecules, anti-cyclin Dl, and anti-transcription factors, may correct and stop the growth of these cells. Anti-angiogenesis factors and anti-integrins may decrease or block metastasis. Combining these new agents with gemcitabine and other chemotherapy agents will hopefully improve the prognosis for patients with pancreatic cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/advanced-pancreatic-cancer-HBxFm9DcpY
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201050-00003
Publisher site
See Article on Publisher Site

Abstract

Carcinoma of the pancreas remains a lethal disease, but much progress has been made in understanding the biology of this cancer. The many genes known to be mutated in the malignant pancreatic cancer cell, especially K-ras and pl6INK4, allow the tumor to grow rapidly, metastasize early and not respond to most conventional chemotherapy agents. Combinations of newer agents that can inhibit the up-regulated growth pathway, including anti-growth factor receptor antibodies, anti-growth factor tyrosine kinases, anti-ras molecules, anti-cyclin Dl, and anti-transcription factors, may correct and stop the growth of these cells. Anti-angiogenesis factors and anti-integrins may decrease or block metastasis. Combining these new agents with gemcitabine and other chemotherapy agents will hopefully improve the prognosis for patients with pancreatic cancer.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References